Post by FirstWord Pharma

New #PsoriaticArthritis (PsA) treatment options keep arriving, but real-world prescribing is being shaped by a few clear forces: payer access, confidence in joint-protection data, and where oral agents truly fit. FirstWord spoke with a dozen KOLs to capture what is starting to change in day-to-day decision-making as new mechanisms, new data, and real-world access constraints collide. We explored: 🔹 Where clinicians are rethinking how they sequence key biologic classes (and what is still holding certain options back) 🔹 What new trial readouts are starting to influence conversations about joint outcomes 🔹 How the market is reacting to the growing push toward oral therapies (and what evidence KOLs want next) 🔹 Why payer dynamics keep showing up as the deciding factor, even when the science is compelling 🔹 The emerging interest in combo approaches and the practical barriers to making them routine Read the full analysis here 👉 https://lnkd.in/epZdjxUA 🔒 This article is exclusive to FirstWord Pharma+ subscribers. If you're not yet a Pharma+ subscriber, contact us to learn how you can gain access to these timely, in-depth insights. #arthritis #biopharma #pharmaceuticals #pharmainsights #pharmatrends #PsA #rheumatology